More than half of the employees at Japanese pharmaceuticals giant Takeda would work in emerging markets a decade from now as the company accelerates its globalisation, Nikkei Asia reported.
According to Takeda, 18% of its 47,000 employees are currently based in emerging markets, compared with 39% in the US and 32% in Europe and Canada. Japan hosts 11% of the workforce.
Christophe Weber, the chief executive, has streamlined Takeda’s operations by selling off consumer pharmaceutical and diabetic treatment businesses. The company now focuses on cancer, digestive and nervous system disorders, as well as rare diseases.
Read the full report: Nikkei Asia
READ MORE:
China Power Crisis May Hit Indian Pharma Sector: BS
India’s Gland Pharma to Make Russian Sputnik V Covid Vaccine
